课题基金 / 基金详情

The HMS Laboratory of Systems Pharmacology

The HMS Laboratory of Systems Pharmacology
HMS 系统药理学实验室
批准号:
8769531
负责人:
PETER Karl SORGER
金额:
$234.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2019-05-31
关键词:
AddressAdvisory CommitteesAreaAsthmaBiochemistryBiological SciencesBiologyBostonCell LineCell modelCellsCellular biologyChemicalsClinicalClinical DataCombined Modality TherapyCommunitiesComplexComputational BiologyCustomDataDevelopmentDisciplineDiseaseDoctor of PhilosophyDoseDrug IndustryDrug KineticsDrug TargetingDrug effect disorderEducationEducation and OutreachEducational workshopEngineeringEnvironmentFacultyFailureFellowshipFibrosisFrequenciesFundingGenomicsGenotypeGoalsGovernmentGrantHealthHospitalsHousingIndividualIndustryInflammatoryInstitutionInternationalKineticsKnowledgeLaboratoriesLeadLifeLinkLungMachine LearningMeasurementMeasuresMedicalMedicineMethodsMiningModelingMolecularMolecular BiologyMusNew Drug ApprovalsOrganismPatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacologyPharmacology and ToxicologyPhosphotransferasesPhysiciansPhysiologicalPhysiologyPopulationPostdoctoral FellowPriceProductivityProteinsQualifyingReaction TimeRecordsReproducibilityResearchResearch PersonnelResearch Project GrantsResistanceResolutionRoleSamplingScienceScientistSignal TransductionSocietiesStagingStructureStudentsSystemSystems BiologyTherapeuticTherapeutic IndexTimeTissuesTranslational ResearchTranslationsUnderserved PopulationVariantWhole OrganismWorkadvanced systembasecancer typecell typecellular imagingcostdesigndrug developmentdrug discoverydrug distributionextracellularimprovedinnovationinsightintravital imagingkinase inhibitormanmathematical modelmeetingsmembermulti-scale modelingnovelnovel strategiesnovel therapeuticsoutreachoutreach programpharmacodynamic modelpharmacokinetic modelprogramsreceptorresponsesuccesssymposiumtheoriestooltranslational medicinetumor xenograftweb siteyoung woman

项目摘要

项目成果

PETER Karl SORGER的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 系统和计算生物学家、内科科学家、药理学家、生物化学家和细胞生物学家将在一个新的系统药理学实验室(LSP)合作,应用测量模型方法来了解治疗药物在多个疾病领域的作用机制。LSP将率先开发以网络为中心的定量药理学和毒理学方法,其中包括在单细胞水平上分析剂量-时间-反应关系,对细胞网络动力学及其药物扰动进行建模,在小鼠和最终在人类身上开发药代动力学和药效学模型,以及使用系统方法来识别和鉴定新药靶标。我们的方法将数学建模与经验测量(包括临床样本和数据的工作)相结合,旨在创建不同时间和物理尺度上的定量和预测性药物反应模型。我们的目标是重振药理学和毒理学作为转化医学的基础学科,发展个性化和精准医学的概念基础,并通过提高药物发现的可预测性来降低药物发现的成本。与业界和FDA的密切互动将有助于解决药物发现和开发方面的生产率差距。LSP的创新之处在于,它的目标是利用基础和翻译药理学中的问题将三个学科(细胞和分子生物学、计算生物学和医学)联系起来,并旨在推动波士顿地区及其他地区的治疗科学。学生和博士后在来自7个机构的18名教职员工、2名独立博士后研究员和2名博士后工作人员的监督下,将在一个新的定制设计的实验室中立即工作。该实验室将主办一个新的治疗学研究生项目和多因素外展活动,这将在国际上推广系统药理学。 这些目标将通过四个相互关联的研究计划(目标1-4)实现,这四个计划是一个致力于有效翻译LSP研究的核心(目标5)、一个教育核心和行政/外联活动(目标6-8)。目标1将侧重于单细胞水平的剂量反应决定因素,包括细胞间变异性在部分反应中的作用以及联合治疗中暴露的时间和顺序的作用。AIM 2将采用网络水平的方法来了解三种类型癌症中激酶抑制剂的治疗、毒性和自相矛盾的药物反应。多重药理学的机制基础和后果也将与正常和病变组织的不同药物反应性一起被检查。AIM 3将通过在细胞、组织和生物体水平上开发药物作用的多尺度模型以及在细胞和亚细胞水平上测量药物分布的新方法来解决PK-PD问题。AIM 4将应用机器学习和因果推理来从哮喘、炎症性疾病和纤维化的临床记录中发现靶标,并采用结构指导的方法来识别“不可用药”靶标的调节者。
英文摘要
PROJECT SUMMARY Systems and computational biologists, physician-scientists, pharmacologists, biochemists and cell biologists will collaborate in a new Laboratory of Systems Pharmacology (LSP) to apply a measure-model approach to understanding the mechanisms of action of therapeutic drugs in multiple disease areas. The LSP will pioneer the development of quantitative network-centric approaches to pharmacology and toxicology that include analysis of dose-time-response relationships at a single-cell level, modeling of cellular network dynamics and their perturbation by drugs, development of pharmacokinetic and pharmacodynamic models in mouse and ultimately in man and use of systematic approaches to identify and qualify new drug targets. Our approach combines mathematical modeling with empirical measurement (including work with clinical samples and data) and aims to create quantitative and predictive drug response models at different temporal and physical scales. We aim to reinvigorate pharmacology and toxicology as foundational disciplines of translational medicine, develop the conceptual underpinning for personalized and precision medicine and lower the cost of drug discovery by improving its predictability. Close interactions with industry and the FDA will help address the productivity gap in drug discovery and development. The LSP is innovative with respect to its goal of using problems in basic and translational pharmacology to link three disciplines (cell and molecular biology, computational biology and medicine) and its aim of advancing therapeutic science in the Boston area and beyond. Students and postdocs supervised by 18 faculty members, 2 independent postdoctoral fellows and two PhD-level staff from 7 institutions will work in immediate proximity in a new custom-designed laboratory. The lab will host a new graduate program in therapeutics and multi-factored outreach activities that will promote systems pharmacology internationally. These goals will be achieved through four inter-linked research programs (Aims 1-4), a core dedicated to efficient translation of LSP research (Aim 5), an education core and administrative/outreach activities (Aims 6-8). Aim 1 will focus on the determinants of dose-response at a single-cell level, including the role of cell-to-cell variability in fractional response and of timing and order-of-exposure in combination therapy. Aim 2 will take a network-level approach to understanding therapeutic, toxic and paradoxical drug responses by kinase inhibitors in three types of cancer. The mechanistic basis and consequences of poly-pharmacology will also be examined along with differential drug responsiveness by normal and diseased tissues. Aim 3 will address PK-PD by developing multi-scale models of drug actions at the level of cells, tissues and organisms and new methods for measuring drug distribution at the cellular and subcellular levels. Aim 4 will apply machine learning and causal reasoning to target discovery from clinical records in asthma, inflammatory disease and fibrosis and pursue a structure-guided approach to identifying regulators of "undruggable " targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
  • 批准号:
    10900843
  • 项目类别:
  • 资助金额:
    $50.3万
  • 财政年份:
    2023
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)
  • 批准号:
    10818803
  • 项目类别:
  • 资助金额:
    $75.74万
  • 财政年份:
    2023
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
  • 批准号:
    10405812
  • 项目类别:
  • 资助金额:
    $25.35万
  • 财政年份:
    2021
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Administrative Core
  • 批准号:
    10494414
  • 项目类别:
  • 资助金额:
    $25.35万
  • 财政年份:
    2021
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
海外基金